ORIC News and Press, Oric Pharmaceuticals Inc. From 02/14/24

SOUTH SAN FRANCISCO and SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat...

2024-01-26 17:08:20 ET More on ORIC Pharmaceuticals ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting ORIC Pharmaceuticals stock rises after it announces $125M private placement Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historica...

2024-01-22 08:44:33 ET More on ORIC Pharmaceuticals ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historical earnings data for ORIC Pharmaceuticals Financial information for ORIC Phar...

Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), and Nextech Pro forma cash and investments expected to fund current operating plan into late 2026 ...

2024-01-09 12:31:02 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Under most financial guidance frameworks, experts advise a long-term approach, which is exactly the opposite ethos when it comes to speculative ideas for high potential stocks. Here, the emphas...

Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination development Initiation of combi...

2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive...

2023-12-21 07:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-15 16:43:55 ET More on ORIC Pharmaceuticals ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting Oric Pharma a new overweight at Wedbush on targeted oncology For further details see: ORIC Pharmaceuticals files to sell 12.14M shares of common stock